Globally, more than 3 million new cases and 10 000 deaths have been reported in the week of 26 December 2022 to 1 January 2023. This represents a reduction in weekly cases and deaths of 22% and 12%, respectively. In the last 28 days (5 December 2022 to 1 January 2023), over 14.5 million cases and ov...er 46 000 new fatalities were reported globally – an increase of 25% and 21%, respectively, compared to the previous 28 days. As of 1 January 2023, over 656 million confirmed cases and over 6.6 million deaths have been reported globally.
In this edition, we include:
The COVID-19 epidemiological update at the global and regional levels.
An update on the circulating SARS-CoV-2 variants of concern (VOCs) and Omicron subvariants under monitoring.
An update on hospitalizations and ICU admissions related to COVID-19.
more
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more
En la Región de las Américas, las poblaciones están envejeciendo y se está experimentando una rápida transición demográfica. El índice de envejecimiento, que refleja el tamaño de los grupos de mayor edad por 100 en comparación con los menores de 15 años, demuestra claramente el aumento de... las personas de 60 años o más. En comparación con las tendencias mundiales, la Región tendrá un mayor número de personas de 60 años o más que de menores de 15 años para el 2030, aproximadamente 25 años antes que el promedio mundial. La pandemia de COVID-19 ha dado pie a una crisis de salud sin precedentes en todo el mundo. Sus efectos en las personas mayores y aquellas con enfermedades subyacentes han puesto de manifiesto los desafíos de abordar sus necesidades durante una emergencia de salud pública. Dada esta transición demográfica, es fundamental reflexionar acerca de la preparación de los sistemas y servicios con vistas a atender las necesidades de este grupo de población, incluidas la mejora de la planificación para casos de emergencia y la protección de las personas mayores.
Esta publicación forma parte de una serie titulada La Década del Envejecimiento Saludable en las Américas: situación y desafíos
more
The key actions, activities, and approaches in this document are organized within each of the 5Cs (see Table 1 in the PDF) and those of the Strategic preparedness and response plan (SPRP) pillars as follows:
National action plan key activities, prioritized for the current context and the current ...understanding of the threat of SARS-CoV-2
A. Transition from emergency response to longer term COVID-19 disease management.
B. Integrate activities into routine systems.
C. Strengthen global health security.
Special considerations for fragile, conflict-affected and vulnerable (including humanitarian) settings
WHO global and regional support to Member States to implement their national action plans
Key guidance documents for reference
This is a living document that will be updated to incorporate new technical guidance in response to the evolving epidemiological situation. National plans should be implemented in accordance with the principles of inclusiveness, respect for human rights, and equity.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
The coronavirus outbreak that began in 2019 (COVID-19) threatens to reverse years of hard-won gains in preventing and treating HIV. Fragile health systems are further stressed as health workers navigate an increased client load and demands at work while also being concerned for their own health and ...that of their families. Health facilities have been redesigned to care for patients with COVID-19, posing challenges to other services. Governments and civil society organizations have redirected scarce resources and shifted programming priorities to respond to the pandemic. Several countries have reported intermittent declines in HIV testing and diagnosis, antenatal care visits, collection of antiretroviral medicines (ARVs) by people living with HIV, and attendance at clinic appointments. Community-based education and support programmes have had to rapidly adapt to restrictions on movement and public gatherings. Children, adolescents, and women have experienced multiple deprivations due to the adverse impact of the pandemic.
more
30 April 2020
| COVID-19: Essential health services
ObjetivoEl objetivodel documento es servir de guía de actuación para el manejo casos de COVID-19 en atención primaria.3.Recomendaciones generalesSe recomienda la colocación de información visual (carteles, folletos, etc.) en lugares estratégicosde los centros de atenció...n primaria (de ahora en adelante CAP)para proporcionar a la poblaciónlas instrucciones sobre higiene de manosehigiene respiratoria.Se ofrecerá una mascarilla quirúrgica a aquellos pacientes que acudan al centro sanitario con síntomas de infección respiratoria aguda.Se debedisponer de dispensadores con solución hidroalcohólica al alcance de la poblacióny el personal. Se deberá disponer de contenedores de residuos, con tapa de apertura con pedal, para la eliminación de los residuos generados.
more
General Objectives
1. Share information on practices on IPC for endemic colonization in a tertiary facility and how those precautions could evolve based on the progress of the event, then further integrating response capabilities, plans and procedures to triage and implement source control measure...s for case of COVID-19 in your facility.
2. Identify challenges in bed occupancy and staff management between different departments.
3. Conduct gap analysis through reflection on how the scenario could play out in your countries.
4. Identify areas for action in your facilities based on the issues explored in the scenario.
more
General Objectives
1. Share information on the progress of your preparation, including response capabilities, plans and procedures to identify and respond to an imported case of COVID-19 in your country.
2. Identify areas of interdependence between health actors and other sectors
3. Conduct g...ap analysis based on the COVID-19 Strategic Preparedness and Response Plan (SPRP)
4. Develop an action plan to enhance your level of readiness, based on the SPRP.
more
Objectifs généraux
1. Partager des informations sur l'avancement de la préparation, y compris les capacités de réponse, les plans et les procédures pour identifier et répondre à des cas de COVID-19 dans votre pays.
2. Identifier les domaines d'interdépendance entre les acteurs de la san...té et d'autres secteurs
3. Mener une analyse des lacunes sur la base du Plan stratégique de préparation et de réponse COVID-19
4. Élaborer un plan d'action pour améliorer votre niveau de préparation, basé sur la liste de contrôle de l'OMS.
more
Indicazioni ad interim - Per un utilizzo regionale delle protezioni per infezione da SARS-CoV-2 nelle attività sanitarie e sociosanitarie (Assistenza a soggetti affetti da CoVID-19) nell’attuale scenario emergenziale SARS-CoV-2
Updated 23 March 2020 (23 Maart 2020)
This document provides guidance on infection prevention and control (IPC) measures for people with suspected or confirmed coronavirus disease (COVID-19) who are experiencing mild symptoms that do not require hospitalisation, therefore self-isolating at home.